Ajanta Pharma Promoters Burger King India Ko Khareedne Nikle! **₹2000 Cr** Ka Deal?

OTHER
Whalesbook Logo
AuthorAarav Shah|Published at:
Ajanta Pharma Promoters Burger King India Ko Khareedne Nikle! **₹2000 Cr** Ka Deal?
Overview

Bhaiyo aur behno, ekdum mast khabar! Ajanta Pharma ke promoters ab pharma se nikal kar seedha Burger King India ki taraf dekh rahe hain. Yeh log Restaurant Brands Asia (RBA) mein controlling stake kharidne ke liye **₹2,000 Crore** ka loan uthane ki soch rahe hain.

Pharma se QSR tak ka bada jump?

Yeh koi choti baat nahi hai, Ajanta Pharma ke promoters ne ek dum bold move liya hai. Woh Restaurant Brands Asia (RBA) mein badi hissedari chahte hain, jo India aur Indonesia mein Burger King chalaati hai. RBA ki market value filhaal lagbhag ₹3,700 Crore ke aas paas hai. Is deal ke liye promoters debt financing, yaani loan ke through paisa judane ki koshish kar rahe hain.

RBA ka current scene kya hai?

Abhi RBA kaafi revenue toh kama rahi hai, lekin profit ke maamle mein thodi phansi hui hai. Company ka Price-to-Earnings (P/E) ratio abhi negative -17.2x chal raha hai (February 2026 tak ke figures ke according). Iska matlab hai ki company loss mein chal rahi hai, jo ki pharma business se bilkul alag hai. Pichhle teen saalon mein RBA ki revenue toh 27.75% tak badhi hai, par profit growth kaafi kamzor rahi hai, aur return on equity (ROE) aur capital employed (ROCE) bhi negative mein hai. Haal hi mein RBA ko ₹1,600 Crore ka investment mila tha, par usse bhi losses khatam nahi hue.

QSR Sector: Growth hai, par profit ka kya?

Dekho, India mein Quick Service Restaurant (QSR) sector boom kar raha hai. Aamdani badh rahi hai, log bahar khana pasand kar rahe hain, aur yeh sector saal mein 15-20% tak grow karne ki ummeed hai. Lekin yahan ek dikkat hai – margins bahut kam hain aur competition zabardast hai. Competition mein Jubilant FoodWorks aur Westlife Foodworld jaise players 90-120x aur 200-500x ke high P/E multiples par trade kar rahe hain, jo unke current earnings se kaafi zyada hai. RBA bhi isi race mein hai.

Ajanta Pharma ka strong foundation

Pharma ke hisaab se Ajanta Pharma ekdum solid hai. Unki company par koi debt nahi hai (debt-to-equity ratio zero), ROE 26.09% hai aur operating margin 27.87% hai. Analysts bhi is stock par bullish hain, 'Buy' rating de rahe hain aur 12-16% ka upside target de rahe hain.

Risk Factor

Ab yeh RBA wali deal promoters ke liye kaafi risky ho sakti hai. QSR market mein survive karna aur profit banana mushkil hai, aur yeh business pharma se bahut alag hai. Agar yeh deal ho gayi toh promoters ko kaafi leverage lena padega, jo financial risk badha sakta hai. RBA ka future growth par zyada depend karta hai, na ki current profit par. Analyst RBA par 'Outperform' rating de rahe hain aur 35-59% tak ka potential upside dikha rahe hain, par promoters ko yeh sab manage karna hoga.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.